- Home
- AZ vs CRDF Comparison
AZ vs CRDF Comparison
Compare AZ & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZ
- CRDF
- Stock Information
- Founded
- AZ 2018
- CRDF 1999
- Country
- AZ Canada
- CRDF United States
- Employees
- AZ N/A
- CRDF N/A
- Industry
- AZ Industrial Machinery/Components
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AZ Industrials
- CRDF Health Care
- Exchange
- AZ Nasdaq
- CRDF Nasdaq
- Market Cap
- AZ 203.7M
- CRDF 240.2M
- IPO Year
- AZ N/A
- CRDF N/A
- Fundamental
- Price
- AZ $6.31
- CRDF $3.41
- Analyst Decision
- AZ
- CRDF Strong Buy
- Analyst Count
- AZ 0
- CRDF 3
- Target Price
- AZ N/A
- CRDF $10.33
- AVG Volume (30 Days)
- AZ 78.0K
- CRDF 1.7M
- Earning Date
- AZ 11-13-2024
- CRDF 02-27-2025
- Dividend Yield
- AZ N/A
- CRDF N/A
- EPS Growth
- AZ N/A
- CRDF N/A
- EPS
- AZ N/A
- CRDF N/A
- Revenue
- AZ $6,628,000.00
- CRDF $688,000.00
- Revenue This Year
- AZ $30.95
- CRDF $25.03
- Revenue Next Year
- AZ $646,436.00
- CRDF N/A
- P/E Ratio
- AZ N/A
- CRDF N/A
- Revenue Growth
- AZ N/A
- CRDF 49.57
- 52 Week Low
- AZ $0.85
- CRDF $1.44
- 52 Week High
- AZ $7.48
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- AZ 43.04
- CRDF 44.35
- Support Level
- AZ $6.25
- CRDF $3.28
- Resistance Level
- AZ $6.93
- CRDF $4.89
- Average True Range (ATR)
- AZ 0.51
- CRDF 0.35
- MACD
- AZ -0.09
- CRDF -0.17
- Stochastic Oscillator
- AZ 17.96
- CRDF 8.70
About AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").